PHARMANUTRA S.P.A. financials
PHARMANUTRA S.P.A.
815600F8217BC7733697 | Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | €131.7M | €115.5M |
| Other income | €2.3M | €1.4M |
| Employee benefits expense | €9.3M | €8.0M |
| Raw materials & consumables used | €6.2M | €5.0M |
| Operating profit (EBIT) | €34.2M | €31.0M |
| Finance costs | €1.1M | €1.6M |
| Profit before tax | €30.2M | €27.2M |
| Income tax expense | €10.3M | €10.6M |
| Profit for the year | €20.0M | €16.6M |
| — attributable to owners | €20.0M | €16.6M |
| — attributable to NCI | €85.0K | €57.0K |
| Total comprehensive income | €19.9M | €16.5M |
| Per share | ||
| Diluted EPS | €2090.00 | €1730.00 |
| Cash flow statement | ||
| Cash generated from operations | €19.6M | €20.4M |
| Net cash from investing activities | -€3.4M | -€2.2M |
| Purchase of PP&E (capex) | €3.1M | €4.2M |
| Net cash from financing activities | -€13.1M | -€21.6M |
| Dividends paid | €9.6M | €8.2M |
| Lease liability payments | -€172.0K | -€613.0K |
| Net change in cash | €3.1M | -€3.4M |
| Balance sheet | ||
| Total assets | €125.2M | €117.4M |
| Non-current assets | €52.3M | €52.4M |
| Property, plant & equipment | €24.1M | €25.7M |
| Current assets | €72.9M | €65.0M |
| Inventories | €8.9M | €6.9M |
| Trade & other receivables | €24.8M | €22.1M |
| Cash & equivalents | €18.6M | €15.5M |
| Total equity | €71.2M | €62.1M |
| — attributable to owners | €71.4M | €62.2M |
| Non-controlling interests | -€112.0K | -€27.0K |
| Non-current liabilities | €23.0M | €27.9M |
| Current liabilities | €31.0M | €27.3M |
| Trade & other payables | €19.9M | €15.8M |
| Derived metrics | ||
| Operating margin | 26.0% | 26.9% |
| Net margin | 15.2% | 14.4% |
| Return on equity | 28.1% | 26.7% |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | -€1.9M | €1.2M |
| Adjustments For Decrease Increase In Other Operating Receivables | -€1.3M | -€1.4M |
| Adjustments For Decrease Increase In Trade Account Receivable | -€2.9M | -€3.0M |
| Adjustments For Depreciation and Amortisation Expense | €3.9M | €3.9M |
| Adjustments For Increase Decrease In Other Operating Payables | €304.0K | €379.0K |
| Adjustments For Increase Decrease In Trade Account Payable | €4.1M | €1.4M |
| Adjustments For Provisions | €1.1M | €972.0K |
| Changes In Inventories of Finished Goods and Work In Progress | -€1.8M | €1.4M |
| Current Tax Assets Current | €842.0K | €545.0K |
| Current Tax Liabilities Current | €1.6M | €2.6M |
| Deferred Tax Assets | €2.2M | €1.4M |
| Dividends Recognised As Distributions To Owners Per Share | €1.00 | — |
| Equity and Liabilities | €125.2M | €117.4M |
| Finance Income | €965.0K | €1.4M |
| Income Taxes Paid Refund Classified As Investing Activities | €752.0K | -€123.0K |
| Increase Decrease In Cash and Cash Equivalents | €3.1M | -€3.4M |
| Increase Decrease Through Transfers and Other Changes Equity | -€1.4M | — |
| Intangible Assets Other Than Goodwill | €24.5M | €23.3M |
| Investments In Subsidiaries Joint Ventures and Associates | €4.0K | €4.0K |
| Issued Capital | €1.1M | €1.1M |
| Liabilities | €54.0M | €55.3M |
| Noncurrent Provisions For Employee Benefits | €5.7M | €4.1M |
| Other Comprehensive Income That Will Be Reclassified To Profit Or Loss Net of Tax | -€73.0K | -€93.0K |
| Other Current Financial Assets | €12.0M | €13.5M |
| Other Current Financial Liabilities | €5.1M | €4.8M |
| Other Current Nonfinancial Assets | €7.8M | €6.5M |
| Other Current Nonfinancial Liabilities | €4.5M | €4.2M |
| Other Expense By Nature | €1.7M | €2.3M |
| Other Longterm Provisions | €1.8M | €4.4M |
| Other Noncurrent Financial Assets | €280.0K | €292.0K |
| Other Noncurrent Financial Liabilities | €15.4M | €19.5M |
| Other Noncurrent Nonfinancial Assets | €1.3M | €1.8M |
| Other Reserves | €56.2M | €49.0M |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | €22.0K | €655.0K |
| Profit Loss From Continuing Operations | €19.9M | €16.6M |
| Services Expense | €84.4M | €69.2M |
| Treasury Shares | €5.9M | €4.6M |
Every line item above is a fact tagged in PHARMANUTRA S.P.A.'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.